| Developers: | Roche |
| Branches: | Pharmaceutics, medicine, health care |
2019: Japan the first approved medicine of Roche for the personalized onkoterapiya
On June 19, 2019 it became known that Japan became the first-ever country which approved medicine of the Swiss company Roche for the personalized therapy of malignant new growths of Rozlytrek (entrectinib). The Ministry of Health, work and social security (MHLW) approved medicine for medical application based on the second phase of the clinical trials (CT) in which it showed efficiency in treatment of ten different types of oncological diseases.
As noted, medicine can be used for treatment of tumors of different localization. In the proceeding KI Rozlytrek showed efficiency in treatment of different oncological diseases, including a breast cancer, a colorectal cancer, neuroendocrine cancer, lung cancer and a pancreas.
Rozlytrek is means of the personalized therapy as affects tumors with rare genetic anomaly (NTRK merge) which can be revealed using testing on biomarkers.
In the nearest future Roche intends to get approval of medicine in Europe and the USA where Bayer already managed to register similar development.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |